Under the trend of band procurement, pharmaceutical companies will accelerate the transformation of innovative drugs in the second half of the year.

, "Pharmaceutical Network Industry Dynamics" Root according to incomplete statistics show that more than 100 pharmaceutical companies have recently disclosed the first half of 2020 results, the total loss of 13.04 billion yuan, has exceeded the 2019 full-year loss amount of 80%.
in fact, this, in addition to the impact of the volume of procurement, is mainly due to the first half of the outbreak period of the medical institutions related departments closed, etc. caused.
but the industry generally believes that with the outbreak gradually under control, the second half of the pharmaceutical enterprises will gradually recover, performance will begin to recover steadily.
, it is worth noting that in the band procurement trend, the industry believes that the important work of domestic pharmaceutical companies in the second half of the year will accelerate the transition to innovative drugs.
after all, the impact of the outbreak is only temporary, as the outbreak is controlled, business will also be restored, the outbreak, pharmaceutical companies need to consider how to increase the risk resistance in the context of the volume of procurement, medical insurance control fees and so on.
industry experts believe that under the trend of the larger trend of drug-purchased medical insurance control fees, accelerating the transition to innovation has clearly become an effective way for pharmaceutical companies to increase their ability to resist risks.
as we all know, in the past, Chinese pharmaceutical enterprises are mostly in the distribution, distribution model to earn the difference, domestic pharmaceutical enterprises research and development costs accounted for the proportion of operating income, compared to multinational pharmaceutical companies have a clear gap.
but in recent years, with the expansion of the volume of procurement, in the crowdout of more and more drug prices of inflated water, benefiting patients at the same time, but also the entire pharmaceutical industry has a far-reaching impact.
not only constantly forceenterprises to adapt to the new market environment, but also increase the strength of innovative research and development of pharmaceutical companies.
, for example, on the evening of May 29, Collum Pharmaceuticals issued a series of announcements, the main issues include the transfer of 30% of the equity to employees on the "Collum Pharmaceutical Research" (generic drug research and development, production, sales) platform for the implementation of employee equity incentives;
industry insiders said that The establishment of market-oriented incentive mechanism, accelerate equity incentives to land, to create a combination of incentive tools, are to better retain innovative talent, especially core talent, for innovative drug research and development cycle of long characteristics, enhance the value of talent accumulation.
recently, Yifan Pharmaceuticals in the release of the 2019 annual report also said that the company will combine the "integration, innovation and internationalization" of the medium- and long-term development strategy, the establishment of Yifan chemical medicine (small molecules) business unit, began to lay out the first imitation of the small molecules "research and marketing" integration.
the division will be Yifan Pharmaceuticals as the main body, by the Yifan Research Institute, Tibet Enhai, import products sales division and domestic and foreign small molecule-related business integration.
in addition to the above enterprises, this year, including Watson Pharmaceuticals, Yiyi Pharmaceuticals, Guangshengtang, Health Yuan, including a number of pharmaceutical companies have also issued organizational structure adjustment, accelerate innovation transformation information.
overall, with the continued in-depth procurement, enterprises have become more and more aware of the importance of transformation in order to have long-term competitiveness.
future, pharmaceutical companies will increase investment in innovation, transform innovative enterprises, and achieve high-quality development will become the new normal of the pharmaceutical industry.
.